share_log

Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35

Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35

古根海姆以买入评级启动对Immunome的报道,宣布目标股价为35美元
Moomoo 24/7 ·  04/15 06:34

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $35.

古根海姆分析师迈克尔·施密特以买入评级开始对Immunome(纳斯达克股票代码:IMNM)进行报道,并宣布目标股价为35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发